JP7098330B2 - Ｈｐｖワクチン - Google Patents

Ｈｐｖワクチン Download PDF

Info

Publication number
JP7098330B2
JP7098330B2 JP2017563914A JP2017563914A JP7098330B2 JP 7098330 B2 JP7098330 B2 JP 7098330B2 JP 2017563914 A JP2017563914 A JP 2017563914A JP 2017563914 A JP2017563914 A JP 2017563914A JP 7098330 B2 JP7098330 B2 JP 7098330B2
Authority
JP
Japan
Prior art keywords
arenavirus
segment
protein
certain embodiments
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017563914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518172A5 (enExample
JP2018518172A (ja
Inventor
オルリンゲル クラウス
モナス トーマス
リリア アンダース
シュミット サラ
ベルカ ウルスラ
スチウェンディンガー マイケル
ワトソン エリザベス
キエフマン ベッティーナ
ヒンテラムスコグラー ジュリア
フールマン ゲルハルト
アスポック アンドレアス
コーエン キャサリン
Original Assignee
ホオキパ バイオテック ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホオキパ バイオテック ジーエムビーエイチ filed Critical ホオキパ バイオテック ジーエムビーエイチ
Publication of JP2018518172A publication Critical patent/JP2018518172A/ja
Publication of JP2018518172A5 publication Critical patent/JP2018518172A5/ja
Priority to JP2022104300A priority Critical patent/JP2022160401A/ja
Application granted granted Critical
Publication of JP7098330B2 publication Critical patent/JP7098330B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2017563914A 2015-06-10 2016-06-09 Ｈｐｖワクチン Active JP7098330B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022104300A JP2022160401A (ja) 2015-06-10 2022-06-29 Ｈｐｖワクチン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562173805P 2015-06-10 2015-06-10
US62/173,805 2015-06-10
US201562254410P 2015-11-12 2015-11-12
US62/254,410 2015-11-12
US201662331158P 2016-05-03 2016-05-03
US62/331,158 2016-05-03
PCT/EP2016/063182 WO2016198531A2 (en) 2015-06-10 2016-06-09 Hpv vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022104300A Division JP2022160401A (ja) 2015-06-10 2022-06-29 Ｈｐｖワクチン

Publications (3)

Publication Number Publication Date
JP2018518172A JP2018518172A (ja) 2018-07-12
JP2018518172A5 JP2018518172A5 (enExample) 2020-04-02
JP7098330B2 true JP7098330B2 (ja) 2022-07-11

Family

ID=56137292

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017563914A Active JP7098330B2 (ja) 2015-06-10 2016-06-09 Ｈｐｖワクチン
JP2022104300A Pending JP2022160401A (ja) 2015-06-10 2022-06-29 Ｈｐｖワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022104300A Pending JP2022160401A (ja) 2015-06-10 2022-06-29 Ｈｐｖワクチン

Country Status (8)

Country Link
US (3) US10669315B2 (enExample)
EP (1) EP3307308A2 (enExample)
JP (2) JP7098330B2 (enExample)
CN (2) CN115197965A (enExample)
AU (2) AU2016274655B2 (enExample)
CA (1) CA2987155A1 (enExample)
HK (1) HK1246183A1 (enExample)
WO (1) WO2016198531A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
CN115197965A (zh) 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
AU2016342376A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Sexually transmitted disease vaccines
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018083220A2 (en) * 2016-11-04 2018-05-11 Hookipa Biotech Ag Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP3606549A1 (en) * 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors
KR20200036873A (ko) * 2017-07-14 2020-04-07 온코루스, 인크. 캡슐화된 폴리뉴클레오티드 및 사용 방법
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
KR102222582B1 (ko) * 2018-02-02 2021-03-04 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
CN109706144A (zh) * 2018-03-07 2019-05-03 江苏润洁生物科技有限公司 一种治疗性hpv核酸疫苗
JP2022507269A (ja) * 2018-11-13 2022-01-18 オンコラス， インコーポレイテッド カプセル化ポリヌクレオチド及び使用方法
CN113347987A (zh) * 2018-11-28 2021-09-03 总医院公司 针对共生病毒的t细胞导向的抗癌疫苗
JP7125760B2 (ja) * 2019-06-14 2022-08-25 国立研究開発法人理化学研究所 免疫系を賦活化する細胞および当該細胞を含む医薬組成物
US20220226467A1 (en) * 2019-06-18 2022-07-21 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
US20220380805A1 (en) * 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
AU2020382378A1 (en) * 2019-11-15 2022-06-30 Daiichi Sankyo Company, Limited Nucleic acid lipid particle vaccine encapsulating HPV mRNA
PH12022553102A1 (en) * 2020-05-14 2023-11-20 Inovio Pharmaceuticals Inc Vaccines for recurrent respiratory papillomatosis and methods of using the same
IL298420A (en) 2020-05-29 2023-01-01 Hookipa Biotech Gmbh Cancer treatment strategies using RNA virus vectors
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
CN115820696A (zh) * 2022-07-28 2023-03-21 怡道生物科技(苏州)有限公司 治疗性多价HPV mRNA疫苗及其制备方法
CN121866044A (zh) 2023-09-15 2026-04-14 吉利德科学公司 沙粒病毒制剂、方法及其用途
WO2025155938A1 (en) * 2024-01-18 2025-07-24 Aov Biopharma, Inc. Vaccine for prevention and treatment of human papilloma virus related cancer
WO2025191169A1 (en) * 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用
CN118599010B (zh) * 2024-05-03 2025-06-27 武汉凯德基诺生物技术有限公司 一种hpv16/18/52治疗性疫苗、制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507536A (ja) 2007-12-27 2011-03-10 ユニヴァーシテト チューリッヒ 複製欠損アレナウイルスベクター

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6869779B1 (en) * 1998-08-27 2005-03-22 Fuso Pharmaceutical Industries, Ltd. Nucleic acid sequence for potentiating the expression of useful gene and method therefor
EP1185615B1 (en) * 1999-04-06 2007-08-01 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
US7223408B2 (en) * 2002-10-03 2007-05-29 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
KR20070101854A (ko) * 2004-11-30 2007-10-17 아에라스 글로벌 티비 백신 파운데이션 재조합 이중 가닥 ｒｎａ 뉴클레오캡시드의 생성 및 제조에유용한 세균 패키징 균주 및 그의 용도
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6219849B2 (ja) 2012-01-24 2017-10-25 サンフォード ヘルス 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
US20150056232A1 (en) * 2012-04-02 2015-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
PL3198008T3 (pl) 2014-09-22 2020-03-31 Regents Of The University Of Minnesota Układ wykorzystujący odwrotną genetykę wirusa pichinde i sposoby zastosowania
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CN115197965A (zh) 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
US10849969B2 (en) 2015-10-23 2020-12-01 Institut Pasteur Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
CN117486979A (zh) 2016-05-18 2024-02-02 巴塞尔大学 作为疫苗载体的三区段pichinde病毒
WO2018083220A2 (en) 2016-11-04 2018-05-11 Hookipa Biotech Ag Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP3606549A1 (en) * 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors
US20220226467A1 (en) * 2019-06-18 2022-07-21 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
IL298420A (en) 2020-05-29 2023-01-01 Hookipa Biotech Gmbh Cancer treatment strategies using RNA virus vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507536A (ja) 2007-12-27 2011-03-10 ユニヴァーシテト チューリッヒ 複製欠損アレナウイルスベクター

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Vaccine，Vol. 22，2004年，p. 520-527
Virology，2011年02月15日，Vol. 411，p. 416-425

Also Published As

Publication number Publication date
JP2018518172A (ja) 2018-07-12
CN107921117B (zh) 2022-06-07
CA2987155A1 (en) 2016-12-15
WO2016198531A3 (en) 2017-01-19
WO2016198531A2 (en) 2016-12-15
US20210024584A1 (en) 2021-01-28
AU2021232660B2 (en) 2025-02-27
US11407790B2 (en) 2022-08-09
US10669315B2 (en) 2020-06-02
AU2016274655A1 (en) 2017-12-21
CN115197965A (zh) 2022-10-18
US20230086859A1 (en) 2023-03-23
JP2022160401A (ja) 2022-10-19
CN107921117A (zh) 2018-04-17
HK1246183A1 (zh) 2018-09-07
US20180179257A1 (en) 2018-06-28
EP3307308A2 (en) 2018-04-18
AU2016274655B2 (en) 2021-06-17
AU2021232660A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20230086859A1 (en) Hpv vaccines
US11040096B2 (en) Therapeutic HPV16 vaccines
US10844096B2 (en) Therapeutic HPV18 vaccines
Daemen et al. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7
JP2018518172A5 (enExample)
Khan et al. Development of a replication‐deficient adenoviral vector‐based vaccine candidate for the interception of HPV16‐and HPV18‐induced infections and disease
EP3452087A1 (en) Therapeutic hpv vaccine combinations
US20250066427A1 (en) Therapeutic papilloma virus vaccines
US7198792B2 (en) Genetic immunization against cervical carcinoma
US20050118139A1 (en) Vaccine using papilloma virus e proteins delivered by viral vector
HK40082300A (en) Hpv vaccines
US20250041399A1 (en) Cmv-based human papillomavirus vaccines
HK1236108A1 (en) Therapeutic hpv16 vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180305

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220629

R150 Certificate of patent or registration of utility model

Ref document number: 7098330

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113